Introduction
Indolent T-cell lymphoproliferative disorder (T-LPD) of the gastrointestinal (GI) tract is a clonal disorder that can affect any site in the GI tract and has an indolent and protracted clinical course. 1 It was first described in 1994 by Carbonnel et al, 2 and since then there were several small series that further characterized this condition and informed us about the diversity in clinical, pathologic, and molecular features. 1, [3] [4] [5] Indolent T-LPD is now included as a provisional entity in the 2016 revision of the World Health Organization classification of lymphoid neoplasms. 6 Optimal therapy for these patients is not yet determined, and most patients had very limited or no response to treatment. In this article, we report disease progression in one of the previously reported patients (case 5) and review the literature. and prednisolone) chemotherapy for a presumptive diagnosis of peripheral T-cell lymphoma (PTCL) in 2012. Following completion of chemotherapy, he reported improvement in symptoms. However, follow-up endoscopy demonstrated persistence of colonic ulceration and inflammation, and colonic biopsy showed persistent T-LPD. He was then treated with thalidomide and prednisone, and he began reporting night sweats in April of 2013. Thalidomide was subsequently discontinued, and he was restarted on infliximab, yet his symptoms did not improve. In August 2013, the patient developed a high fever and was pancytopenic, with elevated liver enzymes and hepatosplenomegaly. Infliximab was stopped, and a liver and bone marrow biopsy were performed and showed more atypical T-cell infiltrate, suggestive of PTCL. The patient died 3 months after PTCL diagnosis of progressive disease.
Formalin-fixed paraffin-embedded sections were processed using an automated immunostainer (Benchmark; Ventana Medical Systems, Phoenix, AZ) and stained with antibodies against CD3, CD4, CD5, CD7, CD8, CD20, CD56, TIA-1, TCR-BF1, and TCR-GD.
T-cell receptor β and γ rearrangements were studied by polymerase chain reaction and capillary electrophoresis of fluorescently labeled polymerase chain reaction products, using standardized kit (In VivoScribe, Technologies, San Diego, CA).
Results
Colon biopsy from 2005 as well as multiple GI biopsies from 2010 to 2012 were available for review. Furthermore, liver and bone marrow biopsies, performed in 2013, were also reviewed. The 2005 colon biopsy showed ulceration and effacement of colonic architecture by a dense lymphoid infiltrate, involving mucosa and submucosa, composed of small lymphocytes with admixed plasma cells. Focal cryptitis was also seen ( Figure 1A-C) . By immunohistochemistry, lymphoid cells appeared to be predominantly CD4-positive with lesser number of CD8-positive cells ( Figure 1D ). Multiple GI biopsies taken from 2010 to 2012 all showed similar histologic findings. Colonic architecture was effaced by a dense, nondestructive lymphoid infiltrate involving mainly the mucosa, with some submucosal extension. The infiltrate was composed of small monotonous lymphoid cells with slightly irregular nuclei and occasional admixed eosinophils (Figure 2) . Some biopsies showed a mild increase in plasma cells and evidence of focal cryptitis. By immunohistochemistry, the infiltrate was positive for CD3, CD7, and TCR-BF1, and negative for CD4, CD8, CD5, CD56, TIA1, and TCR-GD. The atypical double-negative T-cell population was first detected in a biopsy from 2010. T-cell gene rearrangement studies (performed in 2012) on multiple biopsies from different sites showed an identical T-cell clone. The liver biopsy showed periportal and sinusoidal infiltrates of atypical lymphoid cells, predominantly mediumsized with irregular nuclei and small nucleoli. Compared with the previous GI biopsies, this infiltrate was morphologically more atypical, suggestive of a PTCL ( Figure 3A and B). By immunohistochemistry, the cells were positive for CD3 and TCR-BF1 and negative for CD4, CD8, and CD5, similar to the prior GI biopsies ( Figure 3C and D). Moreover, T-cell gene rearrangement studies showed a clonal rearrangement identical to that present in the previous GI biopsies from 2012. The bone marrow showed interstitial and sinusoidal involvement by atypical lymphoid cells, with similar morphology to the liver infiltrate ( Figure 3E and F).
Discussion
We report a patient with indolent T-LPD of the GI tract who progressed into a clonally related, aggressive T-cell lymphoma. Literature review revealed 45 reported cases that fit the criteria for indolent T-LPD of the GI tract, [1] [2] [3] [4] [5] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] with only 4 previously reported patients showing evidence of progression. [3] [4] [5] The first patient who progressed was a 43-year-old male who initially presented with a 2-year history of diarrhea, weight loss, and abdominal pain. Initial sites of involvement included duodenum, jejunum, and ileum. The infiltrate was composed on small mature lymphocytes positive for CD2, CD3, CD4, CD5, and CD7, and negative for CD8. Clonality studies were not performed. Over the period of 12 years, he was treated with a number of agents including tetracycline, chlorambucil, cyclophosphamide, teniposide, and prednisone. His clinical course was characterized by relapsing bouts of diarrhea but was overall stable. His lymph nodes started to enlarge approximately 8 years after initial diagnosis and after 12 years lymphadenopathy was more prominent, and his clinical status started to deteriorate. He was given additional chemotherapy with partial response, but eventually total parenteral nutrition was started and disease progressed to involve colon and liver. His condition worsened, and the patient died 176 months after initial diagnosis. 3 The second reported patient was a 37-year-old male with a clinical history of diarrhea, weight loss, iron, and vitamin deficiencies. The disease initially involved stomach, duodenum, ileum, and colon. Morphologically, the infiltrate was composed of small to medium-sized, irregular lymphocytes expressing CD2, CD3, CD4, CD5 (variable), and CD7 (variable), and negative for CD8. T-cell gene rearrangement studies detected a clonal population in the small intestine and peripheral blood. The patient was treated with budesonide, azathioprine, and prednisone with no significant response. His disease remained stable for 11 years when he developed small bowel perforation. Sections of small intestinal resection showed persistence of smallsized lymphoid infiltrate, as well as extensive infiltrate of large, atypical lymphoid cells with marked pleomorphism and prominent nucleoli. The large cells were positive for CD2, CD3, CD4, and CD30, and were lacking CD5, CD7, and CD8 expression. Findings were consistent with transformation/progression to aggressive T-cell lymphoma. The patient also had liver involvement, as well as persistent peripheral blood involvement by lymphoma. T-cell rearrangement detected a T-cell clone, identical to the one at diagnosis. He died shortly after small intestinal perforation (132 months from initial diagnosis) from sepsis. 4 Recently, Sharma et al 5 reported a series of 10 patients with indolent T-LPD, 2 of which developed overt T-cell lymphoma. One patient had CD4-positive T-LPD and developed a large cell transformation. The other initially had CD8-positive T-LPD and subsequently developed systemic ALK-negative anaplastic large cell lymphoma (ALCL). In summary, among the 5 indolent T-LPD cases (including our case) in the literature that developed more aggressive T-cell lymphoma, 3 were CD4-positive, 1 was double-negative for CD4 and CD8, and 1 was CD8-positive. [3] [4] [5] It is unclear whether the CD8-positive patient who developed systemic ALKnegative ALCL progressed or developed separate, unrelated lymphoma. Molecular studies in that patient identified different clonal T-cell receptor gene rearrangements in the 2 specimens, suggesting that the 2 processes (indolent T-LPD and ALCL) were unrelated. 5 Based on these very limited data, there is some suggestion that CD8-positive cases have somewhat better long-term prognosis with lower rate of progression.
The reasons for the disease progression in our patient are unclear. Described cases of indolent T-LPD are derived from either CD4+ or CD8+ T-cells, and compared with the other reported patients, [1] [2] [3] [4] [5] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] this patient's indolent T-LPD had a CD4/CD8 double-negative phenotype. Interestingly, the biopsy taken early in the disease course (2005) showed histologic findings that can be seen in IBD with a predominantly CD4+ infiltrate. Morphological findings in this early biopsy are similar to later CD4/CD8 double-negative biopsies. Despite significant morphologic overlap between indolent T-LPD and IBD (as previously described in the literature 1 ), we believe that this unusual case represents indolent T-LPD and not IBD. A distinct T-cell clone was detected in our case, which is a characteristic finding in indolent T-LPD and not a usual finding in IBD. Unfortunately, due to lack of material, we were unable to perform clonality studies on the 2005 biopsy and compare the findings with the later biopsies. Moreover, loss of CD4, first detected in the 2010 biopsies, is not a usual finding in IBD. This change in immunophenotype possibly represented a step toward transformation to more aggressive disease.
Differential diagnosis of indolent T-LPD includes several conditions, both neoplastic and nonneoplastic. IBD in the most difficult differential diagnosis since these cases can have many overlapping features with IBD. 1 Our case illustrates the difficulty and the morphologic overlap between the two. Other differential diagnoses to consider, especially in cases of indolent T-LPD that present in the small intestine, include celiac disease and refractory celiac disease. Clinical and laboratory findings are often useful to rule out these entities. 1 Several studies reported on cytogenetic and molecular abnormalities in indolent T-LPD. Published data are relatively limited but CD4-positive cases are better characterized than CD8-positive ones. 1, 3, 4, 15, 16 Conventional cytogenetic analysis showed trisomy 5 in one case and t(4;16)(q26;p13) in another. Both of these cases were CD4-positive indolent T-LPDs. 3 Margolskee et al 4 performed single nucleotide polymorphism array analysis in 3 CD4-positive cases. One case showed no copy number changes (CNCs), while the other showed no pathogenic CNCs except subclonal loss of chromosome X. One patient, who ultimately progressed into aggressive lymphoma, had multiple samples analyzed at different time points in the disease course. Analysis showed loss of chromosome 19q shortly after diagnosis, gains of 1p and 8q 7 years after diagnosis, and multiple gains (involving regions on chromosomes 1, 15, 17, and X) and loss of heterozygosity on chromosome 7q in a sample exhibiting large cell transformation. In a study by Malamut et al, 15 comparative genomic hybridization array (aCGH) was performed and showed heterogeneous, nonrecurrent CNCs (ranging from 1 to 18 per sample). Perry et al 1 analyzed 5 CD8-positive indolent T-LPD cases for STAT3 SH2 domain hot spot mutations and did not show any mutations in the 6 hot spots screened. Edison et al 16 performed targeted sequencing of 40 genes associated with several subgroups of T-cell lymphoma in their CD8-positive indolent T-LPD case but failed to detect any mutations. Recent study by Sharma et al 5 showed a recurrent t(9;17)(p24.1;q21.2) detected by STAT3-JAK2 dual fusions fluorescence in situ hybridization probe. Moreover, 3 of these cases showed STAT3-JAK2 fusion with the identical mRNA breakpoint confirmed by Sanger sequencing, suggesting the role in pathogenesis of this disorder. Six cases in their study (1 CD4-positive, 4 CD8-positive, and 1 double positive) were negative for t(9;17) (p24.1;q21.2). We did not perform cytogenetic analysis or molecular studies in our case.
Our patient received numerous immune-modulating drugs, and overt histologic transformation to PTCL and disease dissemination occurred following CHOP therapy. It is uncertain whether the therapy contributed to the progression of disease, but it is an important question to be answered since many of the indolent T-LPD patients in the literature received different therapy regimens due to initial diagnosis of T-cell lymphoma or IBD. In summary, the etiology and optimal management of indolent T-cell LPD of the GI tract are presently unknown. This case affirms the need for careful long-term follow-up of these patients as some may progress into more aggressive disease.
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